{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:10:02Z","timestamp":1764688202973},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2000,11]]},"DOI":"10.1016\/s0145-2126(00)00075-8","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T14:44:02Z","timestamp":1027608242000},"page":"957-963","source":"Crossref","is-referenced-by-count":11,"title":["Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia"],"prefix":"10.1016","volume":"24","author":[{"given":"X","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Cambier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L","family":"Taksin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Reman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Vekhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Pautas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Soler-Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Ecstein-Fra\u0131\u0308ss\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Archimbaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0145-2126(00)00075-8_BIB1","first-page":"389","article-title":"Phase II trial of mitoxantrone in refractory acute leukemia","volume":"67","author":"Estey","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB2","first-page":"161","article-title":"Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia","volume":"71","author":"Brito-Babapulle","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00255476","article-title":"Antitumor activity of mitoxantrone against murine experimental tumors: Comparative analysis against various antitumor antibiotics","volume":"8","author":"Fujimoto","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB4","first-page":"1139","article-title":"Safety assessment of a new anticancer compound, mitoxantrone, in Beagle dogs; comparison with doxorubicin. I. Clinical observations","volume":"66","author":"Henderson","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0378-4274(82)90163-1","article-title":"Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats","volume":"11","author":"Zbinden","year":"1982","journal-title":"Toxicol Lett"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB6","first-page":"177","article-title":"Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)","volume":"4","author":"Arlin","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00273412","article-title":"Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine","volume":"22","author":"Heinemann","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB8","first-page":"440","article-title":"Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line","volume":"6","author":"Kano","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00282-997-0163-8","article-title":"Mitoxantrone in the treatment of acute myelogenous leukemia: a review","volume":"39","author":"Thomas","year":"1997","journal-title":"Hematol Cell Ther"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.1995.13.1.11","article-title":"Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of etoposide, mitoxantrone, and cytarabine-86 trial","volume":"13","author":"Archimbaud","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB11","first-page":"336","article-title":"Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors","volume":"5","author":"Grant","year":"1991","journal-title":"Leukemia"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB12","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1200\/JCO.1993.11.10.2002","article-title":"Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia","volume":"11","author":"Feldman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.leu.2400623","article-title":"A randomized trial of high- vs. standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia","volume":"11","author":"Feldman","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB14","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of the acute myeloid leukemia: a report of the French-American-British (FAB) Co-Operative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB15","unstructured":"World Health Organization Handbook for Reporting Results of Cancer Treatment. WHO offset publication No.48. Geneva, Switzerland, 1979."},{"key":"10.1016\/S0145-2126(00)00075-8_BIB16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM197902083000603","article-title":"Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography","volume":"300","author":"Alexander","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored Workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/mpo.2950040311","article-title":"Failure of remission induction in acute myelocytic leukemia","volume":"4","author":"Preisler","year":"1978","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB20","first-page":"780a","article-title":"Phase II study of high-dose mitoxantrone-based induction therapy in patients with acute myeloid leukemia","volume":"86","author":"Seiter","year":"1995","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB21","first-page":"93","article-title":"Pilot study of high-dose mitoxantrone and busulfan plus autologous bone marrow transplantation in patients with advanced malignancies","volume":"15","author":"Khalil","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB22","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00007691-199812000-00010","article-title":"High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study","volume":"20","author":"Mollgard","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB23","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1200\/JCO.1996.14.9.2480","article-title":"Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone","volume":"14","author":"Weiss","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB24","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2246::AID-CNCR11>3.0.CO;2-I","article-title":"A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia","volume":"86","author":"Koller","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","article-title":"Mitoxantrone: a new anticancer drug with significant clinical activity","volume":"105","author":"Shenkenberg","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00174158","article-title":"Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update","volume":"3","author":"Benjamin","year":"1985","journal-title":"Invest New Drugs"},{"key":"10.1016\/S0145-2126(00)00075-8_BIB27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/1097-0142(19900801)66:3<418::AID-CNCR2820660303>3.0.CO;2-K","article-title":"Mitoxantrone for refractory and relapsed acute leukaemia","volume":"66","author":"Bezwoda","year":"1990","journal-title":"Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212600000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212600000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,28]],"date-time":"2019-04-28T01:55:45Z","timestamp":1556416545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212600000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["S0145212600000758"],"URL":"https:\/\/doi.org\/10.1016\/s0145-2126(00)00075-8","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}